VYNE Therapeutics Inc. (NASDAQ:VYNE) Director Patrick G. Lepore Purchases 15,000 Shares

VYNE Therapeutics Inc. (NASDAQ:VYNEGet Free Report) Director Patrick G. Lepore acquired 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the purchase, the director now owns 51,472 shares of the company’s stock, valued at $150,298.24. This trade represents a 41.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

VYNE Therapeutics Price Performance

Shares of VYNE traded down $0.18 during midday trading on Thursday, reaching $2.58. The stock had a trading volume of 50,104 shares, compared to its average volume of 167,650. The company has a market capitalization of $38.06 million, a P/E ratio of -3.00 and a beta of 1.30. The firm’s 50 day moving average price is $2.97 and its 200-day moving average price is $2.35. VYNE Therapeutics Inc. has a 52 week low of $1.57 and a 52 week high of $4.30.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new position in VYNE Therapeutics Inc. (NASDAQ:VYNEFree Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises approximately 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th largest holding. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on VYNE. BTIG Research started coverage on VYNE Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $5.75 target price on shares of VYNE Therapeutics in a research report on Tuesday.

Check Out Our Latest Stock Analysis on VYNE

About VYNE Therapeutics

(Get Free Report)

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.

Featured Articles

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.